| Liraglutide and cardiovascular outcomes in type 2 diabetes SP Marso, GH Daniels, K Brown-Frandsen, P Kristensen, JFE Mann, ... New England Journal of Medicine 375 (4), 311-322, 2016 | 7288 | 2016 |
| Semaglutide and cardiovascular outcomes in patients with type 2 diabetes SP Marso, SC Bain, A Consoli, FG Eliaschewitz, E Jódar, LA Leiter, ... New England Journal of Medicine 375 (19), 1834-1844, 2016 | 5528 | 2016 |
| Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes M Husain, AL Birkenfeld, M Donsmark, K Dungan, FG Eliaschewitz, ... New England Journal of Medicine 381 (9), 841-851, 2019 | 1507 | 2019 |
| Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients T Vilsbøll, T Krarup, CF Deacon, S Madsbad, JJ Holst Diabetes 50 (3), 609-613, 2001 | 1205 | 2001 |
| Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud Bmj 344, 2012 | 1113 | 2012 |
| The incretin system and its role in type 2 diabetes mellitus JJ Holst, T Vilsbøll, CF Deacon Molecular and cellular endocrinology 297 (1-2), 127-136, 2009 | 683 | 2009 |
| Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus T Vilsbøll, T Krarup, J Sonne, S Madsbad, A Vølund, AG Juul, JJ Holst The Journal of Clinical Endocrinology & Metabolism 88 (6), 2706-2713, 2003 | 670 | 2003 |
| Incretins, insulin secretion and type 2 diabetes mellitus T Vilsbøll, JJ Holst Diabetologia 47, 357-366, 2004 | 667 | 2004 |
| Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients T Vilsbøll, T Krarup, S Madsbad, J Holst Diabetologia 45, 1111-1119, 2002 | 666 | 2002 |
| Recovery of gut microbiota of healthy adults following antibiotic exposure A Palleja, KH Mikkelsen, SK Forslund, A Kashani, KH Allin, T Nielsen, ... Nature microbiology 3 (11), 1255-1265, 2018 | 649 | 2018 |
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of … T Vilsbøll, M Zdravkovic, T Le-Thi, T Krarup, O Schmitz, JP Courrèges, ... Diabetes care 30 (6), 1608-1610, 2007 | 630 | 2007 |
| Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects T Vilsbøll, H Agersø, T Krarup, JJ Holst The Journal of Clinical Endocrinology & Metabolism 88 (1), 220-224, 2003 | 575 | 2003 |
| Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects T Vilsbøll, T Krarup, S Madsbad, JJ Holst Regulatory peptides 114 (2-3), 115-121, 2003 | 515 | 2003 |
| Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? FK Knop, T Vilsbøll, PV Højberg, S Larsen, S Madsbad, A Vølund, JJ Holst, ... Diabetes 56 (8), 1951-1959, 2007 | 498 | 2007 |
| Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with … PV Højberg, T Vilsbøll, R Rabøl, FK Knop, M Bache, T Krarup, JJ Holst, ... Diabetologia 52, 199-207, 2009 | 456 | 2009 |
| Glucagon-like peptide 1 in health and disease A Andersen, A Lund, FK Knop, T Vilsbøll Nature Reviews Endocrinology 14 (7), 390-403, 2018 | 448 | 2018 |
| Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes T Vilsbøll, J Rosenstock, H Yki‐Järvinen, WT Cefalu, Y Chen, E Luo, ... Diabetes, Obesity and Metabolism 12 (2), 167-177, 2010 | 401 | 2010 |
| Role of gastrointestinal hormones in postprandial reduction of bone resorption DB Henriksen, P Alexandersen, NH Bjarnason, T Vilsbøll, B Hartmann, ... Journal of Bone and Mineral Research 18 (12), 2180-2189, 2003 | 389 | 2003 |
| Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop Diabetes 60 (12), 3103-3109, 2011 | 367 | 2011 |
| Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes JJ Holst, FK Knop, T Vilsbøll, T Krarup, S Madsbad Diabetes care 34 (Suppl 2), S251, 2011 | 326 | 2011 |
